EMA giving increased access to reports on suspected adverse reactions on medicines authorised in EU The EMA will give increased access to reports on suspected adverse reactions to medicines authorised in the European Union, while guaranteeing that personal data will be fully protected. This results from a revision of Eudra Vigilance Access policy adopted by…
